Expert Interview
A second look: Discussing the potential of Lilly's Peresolimab in treating Rheumatoid Arthritis with a focus on the Phase 2 trial data
Ticker(s): LLY, ANABInstitution: University of Nebraska Medical Center
- Professor of Rheumatology at UNMC and Founder and Director of the Rheumatoid Arthritis Investigational Network (RAIN) for the last 25 years.
- Treats 100+ patients with gout.
- Prescribes anti-IL-1 beta drugs for patients with gout, particularly anakinra.
- PI of a 1000 patient gout clinical trial; Research interest in clinical trials and treatment of Gout, clinical trial design, and rheumatoid arthritis.
Roughly how many patients with RA do you manage monthly?
Added By: wilson_adminWhat are your thoughts on the results of the 2023 NEJM paper "A Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis."?
Added By: wilson_adminCould we discuss first those two clinical programs, your view of their clinical data and how they could fit into the current treatment landscape?
Added By: catalin_adminWere physicians excited about a new effective modality that appeared to be safe?
Can you walk through the most impressive to the least impressive of the four measures and why?
What do you think the cancer risk is?
Which endpoint is the most important or do you wait the most when making treatment decisions?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
